Compile Data Set for Download or QSAR
Report error Found 112 Enz. Inhib. hit(s) with all data for entry = 10549
TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292104(US10100049, Example 1 | US10183942, Example 1-8 | ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292104(US10100049, Example 1 | US10183942, Example 1-8 | ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292104(US10100049, Example 1 | US10183942, Example 1-8 | ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292105(US10100049, Example 2 | US10183942, Example 2-3 | ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292105(US10100049, Example 2 | US10183942, Example 2-3 | ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292105(US10100049, Example 2 | US10183942, Example 2-3 | ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292106(US10100049, Example 3 | US10526330, Example 3 | US...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292106(US10100049, Example 3 | US10526330, Example 3 | US...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292107(US10100049, Example 4 | US10183942, Example 4-2 | ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292107(US10100049, Example 4 | US10183942, Example 4-2 | ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292131(BDBM611871 | US10100049, Example 14-7 | US11299492...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292112(US10100049, Example 9 | US10183942, Example 9-2 | ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292112(US10100049, Example 9 | US10183942, Example 9-2 | ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292113(US10100049, Example 10 | US10183942, Example 10 | ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292113(US10100049, Example 10 | US10183942, Example 10 | ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292114(US10100049, Example 11 | US10183942, Example 11 | ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292115(US10100049, Example 12 | US10183942, Example 12 | ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292115(US10100049, Example 12 | US10183942, Example 12 | ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292108(US10100049, Example 5 | US10183942, Example 5 | US...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292108(US10100049, Example 5 | US10183942, Example 5 | US...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292109(US10100049, Example 6 | US10183942, Example 6 | US...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292109(US10100049, Example 6 | US10183942, Example 6 | US...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292110(US10100049, Example 7 | US10183942, Example 7-3 | ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292110(US10100049, Example 7 | US10183942, Example 7-3 | ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292111(US10100049, Example 8 | US10183942, Example 8 | US...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292111(US10100049, Example 8 | US10183942, Example 8 | US...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292119(US10100049, Example 16 | US10100049, Example 7-3 |...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM549192(US11299492, Example 1-1 | US11718616, Example 1-1)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM549192(US11299492, Example 1-1 | US11718616, Example 1-1)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM549193(US11299492, Example 1-3 | US11718616, Example 1-3)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM549193(US11299492, Example 1-3 | US11718616, Example 1-3)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM549193(US11299492, Example 1-3 | US11718616, Example 1-3)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292122(US10100049, Example 1-6 | US11299492, Example 1-6 ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292122(US10100049, Example 1-6 | US11299492, Example 1-6 ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292122(US10100049, Example 1-6 | US11299492, Example 1-6 ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292123(US10100049, Example 1-8 | US11299492, Example 1-8 ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292123(US10100049, Example 1-8 | US11299492, Example 1-8 ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292116(US10100049, Example 13 | US10183942, Example 13 | ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292116(US10100049, Example 13 | US10183942, Example 13 | ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292117(US10100049, Example 14 | US10183942, Example 14-7 ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292117(US10100049, Example 14 | US10183942, Example 14-7 ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292118(US10100049, Example 15 | US10183942, Example 15 | ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292118(US10100049, Example 15 | US10183942, Example 15 | ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292119(US10100049, Example 16 | US10100049, Example 7-3 |...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292119(US10100049, Example 16 | US10100049, Example 7-3 |...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292127(US10100049, Example 4-2 | US11299492, Example 4-2 ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292119(US10100049, Example 16 | US10100049, Example 7-3 |...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292119(US10100049, Example 16 | US10100049, Example 7-3 |...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292119(US10100049, Example 16 | US10100049, Example 7-3 |...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM292129(US10100049, Example 9-1 | US11299492, Example 9-1 ...)
Affinity DataKi: <0.100nMAssay Description:All of the compounds of Examples 1 to 16 and Tables 1 to 19 were tested in one or more of the assays described above. In the following tables, for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/24/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 112 total ) | Next | Last >>
Jump to: